Ticker ADAP – Adaptimmune Therapeutics – sales, description, marketcap – Tickerday.com

ADAP

Adaptimmune Therapeutics

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 1.18B; Volume: 46.03K; AvgVol 3m: 740.21K; Beta: –;

Cost estimate:

P/E: –; EPS: -1.10; EPS growth quarter/prev quarter: 44.40%;

EPS growth this year: -33.20%; EPS growth past 5 years: -46.40%;

EPS ttm: -1.10;

P/S: 608.99; P/B: 2.79; P/Cashflow: 3.20; P/FCF: ;

Sales: 2.23M; Sales growth quarter/prev quarter: 150.00%; Sales growth past 5 years: -30.30%;

Profitability:

Gross Margin: ; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -42.70%; ROE – return on equity: -58.60%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 0.10%; Insider Transactions:-80.46%;

Institutional Ownership: 83.20%; Institutional Transactions: 34.80%;

Data update: 07.10.2020.